By Fineline Cube 
Hopstem Biotechnology announced the completion of the first close of its nearly RMB 200 million Series C financing round. The round was participated in by new shareholders Tasly Capital, HBVC, and Guangzhou Health Investment, along with existing shareholder Longmen Capital. The proceeds will be used to accelerate the company’s clinical development across multiple indications and to prepare for commercial‑scale production.
Financing Overview
| Item | Detail |
|---|---|
| Company | Hopstem Biotech |
| Round | Series C (first close completed) |
| Size | Nearly RMB 200 million |
| New Investors | Tasly Capital, HBVC, Guangzhou Health Investment |
| Existing Investor | Longmen Capital |
| Use of Proceeds | Accelerate clinical development across multiple indications; prepare for commercial‑scale production |
Company Profile & Technology Platform
- Founded: January 2017 — a global innovative biotechnology company dedicated to developing iPSC‑derived off‑the‑shelf cell therapy products
- Core IP: Leading global patents and technological advantages in iPSC reprogramming, pluripotent stem cell neural differentiation, and various cell engineering approaches
- Manufacturing & Analytics:
- Established an iPSC cell product CMC platform
- Closed automated production processes
- Multiple innovative analytical methods
- Licensing Assets: GMP‑grade iPSC cell lines available for commercial licensing both domestically and internationally, alongside a multi‑asset product pipeline
Lead Asset: hNPC01
| Item | Detail |
|---|---|
| Product | hNPC01 (human forebrain neural progenitor cells) |
| Regulatory Status | Earliest iPSC cell product of its kind to receive both CDE and FDA IND approvals in China, with the fastest development progress |
| Clinical Stage | Phase 1 clinical trials completed |
| Designations | FDA Fast Track designation; Regenerative Medicine Advanced Therapy (RMAT) certification |
| Target Conditions | Stroke, traumatic brain injury sequelae, cerebral palsy, epilepsy, and other conditions with major unmet medical needs |
Market Impact & Outlook
- Investor Validation: Participation from three new institutional investors alongside an existing shareholder signals continued confidence in Hopstem’s iPSC platform at a time when cell therapy funding has grown more selective.
- Off‑the‑Shelf Positioning: Allogeneic, iPSC‑derived cell therapies aim to overcome the cost and scalability constraints of autologous products, and Hopstem’s closed automated manufacturing and CMC capabilities are central to that thesis.
- Regulatory Momentum: hNPC01’s dual CDE/FDA IND status, completed Phase 1 program, and both Fast Track and RMAT designations position it among the most clinically advanced iPSC‑derived neural cell products globally.
- Dual Revenue Pathways: Beyond the clinical pipeline, commercial licensing of GMP‑grade iPSC cell lines offers a near‑term monetization channel domestically and internationally, while the Series C proceeds fund the push toward commercial‑scale production.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Hopstem Biotech’s financing, clinical development of hNPC01, and commercialization preparations. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and manufacturing scale‑up.-Fineline Info & Tech